THALES
6.6.2022 14:02:12 CEST | Business Wire | Press release
As organisations continue their digital transformation journeys and move more of their workloads, networking, and security frameworks to the cloud, there is increasing pressure for businesses to rollout sufficiently robust security solutions to safeguard their networks. A long-standing collaboration between the two global cybersecurity leaders, Thales and Palo Alto Networks, will help support this widespread cloud migration, allowing organisations to implement Zero Trust security systems at scale. Through three technology integrations, businesses will gain access to Internal Resources within a robust, highly resilient security architecture.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220606005079/en/
This news comes at a time where cloud transformation at enterprise-level is occurring at pace to support an increasingly hybrid working world. In line with this shift, it is critical that businesses secure distributed IT environments that no longer have a defined physical security perimeter. The combination of identity aware contextual access controls and multi-factor authentication systems will enable secure cloud transformation whilst supporting remote workforces, allowing employees to safely access any resource, from anywhere, and on any device.
Three key integrations
The integrations will minimise the threat of data breaches from identity compromise by implementing strong, adaptive authentication at the network edge and by ensuring automated remediation workflows in the event of an untrusted access event.
By integrating Thales’ SafeNet Trusted Access across Palo Alto Networks Prisma® Access, GlobalProtect, ML-Powered Next Generation Firewalls, and Cortex® XSOAR technologies, businesses will be able to deploy a Zero Trust model across a suite of solutions. Organisations will benefit from secure and adaptive multi-factor authentication, access management across edge solutions, network security policies, incident response and threat intelligence management.
“Thales has partnered with us to help support customers through their digital transformation journeys, and in collaboration we are well primed to provide a zero trust approach with authentication, SOC security and ZTNA solutions. With these integrations, businesses are able to seamlessly secure access to hybrid and cloud environments, detect suspicious account activity, automatically trigger alerts and enforce stronger access policies in real-time,” said Tana Rosenblatt, VP Technology Partnerships, at Palo Alto Networks.
“The business threat landscape is evolving rapidly, leading to an increase in the scale and complexity of risks being faced by many of our clients. As organisations move their network security to the cloud, it becomes more difficult to implement holistic security controls. We are excited to be able to work with Palo Alto Networks and offer organisations a clear path towards identity-aware Zero Trust security.
By applying and enforcing adaptive and multi-factor authentication at the network edge, and by responding to and stopping untrusted access events in real-time, Thales and Palo Alto Networks ensure organisations can make the move to the cloud successfully and securely,” concluded Francois Lasnier, VP Access Management Products at Thales.
For businesses looking to roll out Zero Trust frameworks within their networks, Thales and Palo Alto Networks security solutions are available to integrate now. To learn more about rolling out Zero Trust frameworks using Thales and Palo Alto Networks security solutions, join our RSA Conference roundtable session that discusses identity centric Zero Trust with Palo Alto Networks by reserving one of the limited seats here .
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum technologies – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organizations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2021, the Group generated sales of €16.2 billion.
PLEASE VISIT
View source version on businesswire.com: https://www.businesswire.com/news/home/20220606005079/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 01:56:00 CEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
